Pfizer Inc
NYSE:PFE
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
21.59
27.37
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
PFE
stock under the Base Case scenario is
28.4
USD.
Compared to the current market price of 25.65 USD,
Pfizer Inc
is
Undervalued by 10%.
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Pfizer Inc.
Fundamental Analysis
PFE Profitability Score
Profitability Due Diligence
Score
PFE Solvency Score
Solvency Due Diligence
Score
Select up to 3 indicators:
Select up to 3 indicators:
Pfizer’s revenue from its COVID-19 vaccine may sharply fall as the pandemic fades, creating reliance on a still-emerging pipeline that may struggle to offset the loss of high-margin vaccine income.
Patent expirations on blockbuster drugs like Ibrance and Xeljanz pose a significant threat to long-term sales growth, as cheaper generics or biosimilars could rapidly erode market share.
Amid rising scrutiny over drug pricing and intensifying regulatory efforts in major markets, Pfizer's historically premium-priced portfolio may face margin pressure and unpredictable pricing environments.
A robust late-stage pipeline in immunology, oncology, and vaccine segments could yield multiple blockbuster approvals, helping Pfizer not only offset patent-cliff losses but also drive new revenue growth.
The company’s healthy balance sheet and solid cash flows enable strategic acquisitions of smaller biotech innovators, bolstering Pfizer’s R&D capabilities and strengthening its future product portfolio.
Pfizer’s successful collaboration with BioNTech on the COVID-19 vaccine highlights growing expertise in mRNA technology, positioning the firm to capitalize on novel treatments and next-generation vaccines beyond the pandemic.
Revenue & Expenses Breakdown
Pfizer Inc
Balance Sheet Decomposition
Pfizer Inc
Pfizer Inc
Free Cash Flow Analysis
Pfizer Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Pfizer Inc
Wall St
Price Targets
PFE Price Targets Summary
Pfizer Inc
According to Wall Street analysts, the average 1-year price target for
PFE
is 29.42 USD
with a low forecast of 23.23 USD and a high forecast of 39.42 USD.
Dividends
Current shareholder yield for
PFE is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
PFE
stock under the Base Case scenario is
28.4
USD.
Compared to the current market price of 25.65 USD,
Pfizer Inc
is
Undervalued by 10%.